Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT07001436 | May → Aug 2025 overdue | impaired renal function disease | Henan Genuine Biotech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07002281 | Jul → Oct 2024 | — | Henan Genuine Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06991634 | Apr 2023 | — | Henan Genuine Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07002242 | Jul → Aug 2022 | — | Henan Genuine Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07002268 | Mar → May 2022 | — | Henan Genuine Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07001501 | Feb → Apr 2022 | — | Henan Genuine Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07001488 | Feb → May 2022 | — | Henan Genuine Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07002255 | Dec 2021 → Mar 2022 | — | Henan Genuine Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07002229 | Dec 2021 → Feb 2022 | — | Henan Genuine Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05682599 | Jan → Apr 2023 | COVID-19 | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 2 | NCT04109183 | Oct 2017 → Jan 2019 | AIDS | Henan Genuine Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05633433 | Dec 2022 → Jun 2024 | COVID-19 | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07307586 | Sep 2025 → Dec 2026 expected | chronic hepatitis B virus infection | Zhigang Ren | Recruiting | No outcome recorded |
| Phase 3 | NCT05033145 | Jan → Jul 2022 | COVID-19 | HRH Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 3 | NCT04668235 | Apr 2021 → Aug 2022 | COVID-19 | HRH Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 3 | NCT04303598 | Apr 2020 → May 2022 | HIV infectious disease | Henan Genuine Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05697055 | Jan → May 2023 | COVID-19 | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05642910 | Oct 2022 → Jan 2023 | COVID-19 | Southeast University, China | Unknown | No outcome recorded |
| — | NCT04425772 | Jun → Aug 2020 | COVID-19 | Henan Genuine Biotech Co., Ltd. | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05689034 Comparator | Apr 2023 → Jun 2025 overdue | COVID-19 | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Azvudine | “Azvudine (FNC), a new class I drug with independent intellectual property rights, is a novel nucleoside reverse transcriptase inhibitor with good inhibitory activity against...” NCT04109183 ↗19“A Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19）” NCT04425772 ↗ “CHB patients with Azvudine treatment” NCT07307586 ↗ |
| Known as | FNC | “Azvudine (FNC), a new class I drug with independent intellectual property rights, is a novel nucleoside reverse transcriptase inhibitor with good inhibitory activity against...” NCT04109183 ↗10“Azvudine(FNC)，a nucleoside reverse transcriptase inhibitor, make itself a better candidate to be co-formulated in other anti-HIV therapies” NCT07002242 ↗ “Azvudine(FNC)，a nucleoside reverse transcriptase inhibitor, make itself a better candidate to be co-formulated in other anti-HIV therapies” NCT07002268 ↗ “A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Itraconazole Capsules (ICZ)” NCT07001501 ↗ “A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rifampicin Capsules (RIF)” NCT07002255 ↗ “Azvudine (FNC), a nucleoside reverse transcriptase inhibitor” NCT06991634 ↗ “Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)” NCT07002229 ↗ “Azvudine(FNC)，a nucleoside reverse transcriptase inhibitor” NCT07002281 ↗ “Azvudine(FNC)，a nucleoside reverse transcriptase inhibitor” NCT07001488 ↗ “Azvudine(FNC)，a nucleoside reverse transcriptase inhibitor” NCT07001436 ↗ |
| Known as | RO 0622 | ChEMBL registry synonym — accepted as the source's own label CHEMBL519846 ↗ |
| Action | Inhibit | “good inhibitory activity against HIV-1” NCT04109183 ↗ |
| Modality | Small molecule | “is a novel nucleoside reverse transcriptase inhibitor” NCT04109183 ↗ |
| Route | Oral | “Azvudine 5 mg, QD PO, D1-D7” NCT05633433 ↗ |